Claims for Patent: 9,351,943

Summary for Patent: 9,351,943

Title:	Anti-fibroblastic fluorochemical emulsion therapies
Abstract:	The present invention is directed to compositions and methods targeting tissue resident cells, such as fibroblasts, in a subject harboring conditions or at risk for conditions that would benefit from anti-fibroblastic therapy. The present invention relates to the use of fluorochemical compositions and methods of delivery that result in retention of the fluorochemical composition and any bioactive agent delivered in combination with the fluorochemical composition.
Inventor(s):	McLeay; Matthew T. (Omaha, NE)
Assignee:
Application Number:	13/175,305
Patent Claims:	1. A method of inhibiting the activity of at least one fibroblast cell comprising administering an amount of an aerosol fluorochemical composition directly to the location of the fibroblast cell, wherein the fluorochemical composition comprises: a. a fluorochemical; b. a bioactive agent is an antibody based agent that is selected from the group consisting of alemtuzumab, bevacizumab, cetuximab, gemtuzumab ozogamicin, ibritumomab tiuxetan, ofatumumab, panitumumab, rituximab, tositumomab, trastuzumab, trastuzumab DM1, and combinations thereof ; and, c. an emulsion agent. 2. The method of claim 1, further comprising administering an agent selected fromthe group consisting of anti-cancer agents, respiratory agents, antibodies, antibiotics, anti-virals, mydriatics, anti-glaucomic agents, anti-inflammatories, anti-histaminetics, anti-neoplastics, anesthetics, ophthalmic agents, cardiovascular agents, immunoactive agents, imaging agents, immunosuppressive agents, gastrointestinal agents, and combinations thereof. 3. The method of claim 2, wherein the anti-cancer agents are selected from the group consisting of chemotherapy agents, antibody based agents, tyrosine-kinase inhibitor based agents, and combinations thereof. 4. The method of claim 3, wherein the chemotherapy agent is selected from the group consisting of actinomycin D, aldesleukin, alitretinoin, all-trans retinoic acid/ATRA, altretamine, amascrine, asparaginase, azacitidine, azathioprine, bendamustine hydrochloride, bexarotene, bicalutamide, bleomycin, bortezomib, busulfan, capacitabine, carboplatin, carmustine bcnu, chlorambucil, cisplatin/cisplatinum, cladribine, cyclophosphamide/cytophosphane, cytabarine, dacarbazine, daunorubicin/daunomycin, denileukin diftitox, dexrazoxane, docetaxel, doxorubicin, doxorubicin, doxorubicin liposomal, epirubicin, etoposide, fludarabine, fluorouracil 5-FU, gemcitabine, goserelin, hydrocortisone, hydroxyurea, idarubicin, ifosfamide, interferon alfa, irinotecan CPT-11, lapatinib, lenalidomide, leuprolide, mecholorethamine/chlormethine/mustine/HN2, mercaptopurine, methotrexate, methylprednisolone, mitomycin, mitotane, mitoxantrone, octreotide, oprelvekin, oxaliplatin, paclitaxel, paclitaxel proteinbound, pamidronate, pazopanib, pegaspargase, pegfilgrastim, PEG interferon, Pemetrexed, Pentostatin, Phenylalanine mustard, plicamycin/mithramycin, prednisone, prednisolone, procarbazine, raloxifene, romiplostim, sargramostim, sorafenib, streptozocin, sunitinib, tamoxifen, temozolomide, temsirolimus, teniposide, thalidomide, thioguanine, thiophosphoamide/thiotepa, thiotepa, topotecan hydrochloride, toremifene, tretinoin, valrubicin, vinblastine, vincristine, vindesine, vinorelbine, vorinostat, zoledronic acid, and combinations thereof. 5. The method of claim 3, wherein the tyrosine-kinase inhibitor based agent is selected from the group consisting of axitinib, bafetinib, bosutinib, cediranib, crizotinib, dasatinib, erlotinib hydrochloride, gefitinib, imatinib, lapatinib, lestaurtinib, neratinib, nilotinib, ponatinib, quizartinib, regorafenib, ruxolitinib, sunitibin, tofacitinib, vandetanib, vatalanib, and combinations thereof. 6. The method of claim 1, wherein the fluorochemical is selected from the group consisting of bis(F-alkyl) ethanes, cyclic fluorocarbons, perfluorinated amines, brominated perfluorocarbons, perfluorooctyl chloride, perfluorooctyl hydride, perfluoroalkylated ethers, perfluoroalkylated polyethers, fluorocarbonhydrocarbon compounds, and combinations thereof. 7. The method of claim 1, wherein the emulsion agent is selected from the group consisting of phospholipids, nonionic surfactants, fluorinated surfactants, and combinations thereof. 8. The method of claim 7, wherein the phospholipid is selected from the group consisting of lecithin, egg yolk phospholipids, and combinations thereof. 9. The method of claim 7, wherein the fluorinated surfactant is selected from the group consisting of triperfluoroalkylcholate, perfluoroalkylcholestanol, perfluoroalkyloxymethylcholate, C.sub.3F.sub.7 O(CF.sub.2).sub.3C(.dbd.O)NH(CH.sub.2).sub.3N(O)(CH.sub.3).sub.2 (XMO10), fluorinated polyhydroxylated surfactants, and combinations thereof. 10. The method of claim 8, wherein the nonionic surfactant is selected from the group consisting of polyoxyethylene-polyoxypropylene copolymers, pluronic, and combinations thereof.

Details for Patent 9,351,943

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2030-07-01
Clinigen, Inc.	PROLEUKIN	aldesleukin	For Injection	103293	05/05/1992		2030-07-01
Partner Therapeutics, Inc.	LEUKINE	sargramostim	For Injection	103362	03/05/1991		2030-07-01
Partner Therapeutics, Inc.	LEUKINE	sargramostim	Injection	103362	03/05/1991		2030-07-01
Servier Pharmaceuticals Llc	ONCASPAR	pegaspargase	Injection	103411	02/01/1994		2030-07-01
Wyeth Pharmaceuticals Inc.	NEUMEGA	oprelvekin	For Injection	103694	11/25/1997		2030-07-01